Tome Biosciences recently exited stealth mode with almost a quarter of a billion dollars in funding. The company has developed a new approach to gene editing, programmable genomic integration (PGI), which it says represents the final chapter in genomic medicines.  We discussed the company’s formation and approach with the CEO and president of Tome, Rahul Kakkar.  00:45-04:30: About Tome Biosciences 04:30-05:37: Is there still a role for CRISPR-Cas9? 05:37-07:41: Raising funds for Tome 07:41-11:15: What are the benefits of PGI? 11:15-12:54: How do you find and change the genetic code? 12:54-15:04: What is the difference between integrase-mediated PGI and ligase-mediated PGI?  15:04-16:41: Are there dangers with these techniques?  16:41-17:30: Is the editing reversible? 17:30-20:11: What diseases or conditions will you be addressing? 20:11-21:38: Is success considered to be curing diseases? 21:38-25:16: How will you address costs and scalability? 25:16-29:03: Can you explain this being the final chapter in genomic medicine? 29:03-30:24: How will you fine tune these techniques? 30:24-31:24: What was the reason for the takeover of Replace Therapeutics?  31:24-32:26: What are the next steps? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter